|1984-1988||Ph.D. (Pharmaceutical Sciences with Emphasis in Pharmacokinetics),
Faculty of Pharmacy, University of Alberta, Edmonton, Alberta, Canada
|1974-1979||Pharm.D., Faculty of Pharmacy, University of Tehran, Tehran, Iran|
Dr. Mehvar’s research is focused on the role of the liver in drug disposition and the pharmacological approaches to treat liver diseases. With regard to drug disposition, recent studies in his laboratory have focused on the inflammatory mediators, such as cytokines and nitric oxide, affecting cytochrome P450-mediated drug metabolism. As for the liver diseases, the focus has been on the reduction of rejection in liver transplantation and attenuation of cold and warm ischemia-reperfusion (IR) injury. The latter studies have resulted in the development of a novel dextran prodrug of methylprednisolone, which selectively accumulates in the liver, releasing the active drug for an extended period of time (> two weeks) and reducing the IR injury and graft rejection after transplantation in animal models. Very recently, his laboratory has focused on the effects of hepatic IR injury on the transporter- and/or cytochrome P450-mediated hepatobiliary and brain disposition of drugs. In particular, his group is interested in investigating how liver diseases might affect the blood-brain barrier permeability and neurologic complications observed after liver surgical procedures. Dr. Mehvar also conducts educational research related to ability-based learning approaches, online tools for active learning in pharmacokinetics, and curricular outcome assessment strategies.